PPD (NYSE:PPDI) is expanding its consulting services into four new areas, signaling the kinds of services that the Wilmington, North Carolina clinical research organization believes will be growth opportunities.
The CRO’s consulting arm, PPD Consulting, has added biosimilars, adaptive trial design, China regulatory strategy and cardiovascular outcome studies as four new practice areas for the division.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We have aligned our consulting practice to the areas where we continue to see a strong need for our services to help our clients address significant regulatory and market challenges,” Chief Medical Officer Dr. Christine Dingivan said in a prepared statement.
Biosimilars are new versions of biopharmaceutical products that follow patent expiry. Adaptive trial design allows researchers to make adjustments to clinical trials in mid-study in order to have faster, more efficient, and ultimately, less expensive trials. PPD’s addition of a China regulatory practice area follows CRO acquisitions that the company has made in the region. The cardiovascular outcome studies practice area comes as regulators are increasingly requiring more data about the cardiovascular impacts of drug candidates.
CROs have been adding consulting services or expanding existing consulting offerings in an effort to broaden their offerings to pharmaceutical companies. In January, Raleigh, North Carolina-based INC Research acquired consulting firm AVOS Life Sciences. Later that month, inVentiv Health acquired CRO i3 Research as well as Campbell Alliance, a Raleigh consulting firm.
